BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Fundamental Analysis & Valuation

NASDAQ:BGMSP • US23254L2079

Current stock price

1.44 USD
-0.95 (-39.75%)
At close:
1.1 USD
-0.34 (-23.61%)
After Hours:

This BGMSP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BGMSP Profitability Analysis

1.1 Basic Checks

  • In the past year BGMSP has reported negative net income.
  • BGMSP had a negative operating cash flow in the past year.
  • In the past 5 years BGMSP always reported negative net income.
  • BGMSP had a negative operating cash flow in each of the past 5 years.
BGMSP Yearly Net Income VS EBIT VS OCF VS FCFBGMSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • BGMSP has a Return On Assets of -85.49%. This is in the lower half of the industry: BGMSP underperforms 70.13% of its industry peers.
  • Looking at the Return On Equity, with a value of -98.28%, BGMSP is in line with its industry, outperforming 45.47% of the companies in the same industry.
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BGMSP Yearly ROA, ROE, ROICBGMSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • BGMSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGMSP Yearly Profit, Operating, Gross MarginsBGMSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BGMSP Health Analysis

2.1 Basic Checks

  • BGMSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BGMSP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BGMSP has been increased compared to 5 years ago.
  • BGMSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGMSP Yearly Shares OutstandingBGMSP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
BGMSP Yearly Total Debt VS Total AssetsBGMSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -75.15, we must say that BGMSP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BGMSP (-75.15) is worse than 93.45% of its industry peers.
  • There is no outstanding debt for BGMSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -75.15
ROIC/WACCN/A
WACC9.37%
BGMSP Yearly LT Debt VS Equity VS FCFBGMSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • BGMSP has a Current Ratio of 6.43. This indicates that BGMSP is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.43, BGMSP is doing good in the industry, outperforming 63.78% of the companies in the same industry.
  • A Quick Ratio of 5.07 indicates that BGMSP has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.07, BGMSP perfoms like the industry average, outperforming 56.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 5.07
BGMSP Yearly Current Assets VS Current LiabilitesBGMSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BGMSP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 96.34% over the past year.
  • Looking at the last year, BGMSP shows a quite strong growth in Revenue. The Revenue has grown by 9.46% in the last year.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%

3.2 Future

  • BGMSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.16% yearly.
  • BGMSP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1049.89% yearly.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A

3.3 Evolution

BGMSP Yearly Revenue VS EstimatesBGMSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2023 2024 2025 2026 2027 20M 40M 60M 80M
BGMSP Yearly EPS VS EstimatesBGMSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100K -200K -300K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BGMSP Valuation Analysis

4.1 Price/Earnings Ratio

  • BGMSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BGMSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGMSP Price Earnings VS Forward Price EarningsBGMSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGMSP Per share dataBGMSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BGMSP's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. BGMSP Dividend Analysis

5.1 Amount

  • BGMSP has a Yearly Dividend Yield of 41.67%, which is a nice return.
  • In the last 3 months the price of BGMSP has falen by -55.69%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 0.78, BGMSP pays a better dividend. On top of this BGMSP pays more dividend than 99.81% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, BGMSP pays a better dividend.
Industry RankSector Rank
Dividend Yield 41.67%

5.2 History

  • BGMSP has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A
BGMSP Yearly Dividends per shareBGMSP Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.1 0.2 0.3 0.4 0.5

5.3 Sustainability

DPN/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
BGMSP Yearly Income VS Free CF VS DividendBGMSP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

More info and screens

Find the best dividend stocksShow peers with best dividend

BGMSP Fundamentals: All Metrics, Ratios and Statistics

BIO GREEN MED SOLUTION - BGMS 6 PERP

NASDAQ:BGMSP (3/20/2026, 8:00:01 PM)

After market: 1.1 -0.34 (-23.61%)

1.44

-0.95 (-39.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-31
Inst Owners1.65%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner ChangeN/A
Market Cap7.06M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 41.67%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date01-22
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.11
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1.28
EV/EBITDA N/A
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 5.07
Altman-Z -75.15
F-Score5
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP Fundamental Analysis FAQ

What is the fundamental rating for BGMSP stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGMSP.


What is the valuation status of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP). This can be considered as Overvalued.


How profitable is BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) stock?

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a profitability rating of 0 / 10.